- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05662358
Denosumab vs Alendronate After Vertebroplasty
February 18, 2023 updated by: Shenzhen People's Hospital
Denosumab vs Alendronate in Patients With Osteoporotic Vertebral Compression Fracture After Percutaneous Vertebroplasty: A Randomized Controlled Trial
Osteoporotic vertebral compression fracture (OVCF) patients had a proportion of secondary fractures after percutaneous vertebroplasty (PVP).
Denosumab and alendronate is both effective to prevent bone loss for OVCF postmenopausal women.
However, trial evidence comparing effect of denosumab vs zoledronate after PVP was unknown.
The study aims to assess the efficiency of denosumab vs alendronate for OVCF patients bone mineral density (BMD), bone turnover markers (BTMs), secondary fracture and adverse events after PVP
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Whether denosumab was non-inferior than alendronate in improving bone mineral density (BMD), bone turnover markers (BTMs), functional status questionnaires, and secondary fracture in elderly patients with OVCF after PVP remains unknown.
A prospective, randomized, placebo-controlled clinical trial in OVCF patients with PVP was performed.
This study aimed to investigate the efficiency of denosumab vs alendronate on BMD, BTMs, functional status, secondary fracture rate, and adverse events in OVCF patients after PVP during a 12-month follow-up period.
Study Type
Interventional
Enrollment (Anticipated)
90
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Hongyu Wang, Doctor
- Phone Number: 18241651300
- Email: wanghongyu790039663@126.com
Study Contact Backup
- Name: Song Wang, Master
- Phone Number: 18085243269
- Email: 2362380008@qq.com
Study Locations
-
-
Guangdong
-
Shenzhen, Guangdong, China, 518000
- Recruiting
- ShenZhen People's Hospital
-
Contact:
- Hongyu Wang, Doctor
- Phone Number: 18241651300
- Email: wanghongyu790039663@126.com
-
Contact:
- Song Wang, Master
- Phone Number: 18085243269
- Email: 2362380008@qq.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Must be age between 50 and 85 years old
- X-ray diagnosis of 1 or 2 segment vertebral compression fractures from T4 to L5
- Bone mineral density T value less than -1 via dual-energy X-ray
- A recent fracture history less than 6 weeks
- MRI show bone marrow edema of fractured vertebrae
- low back pain, local paravertebral tenderness
Exclusion Criteria:
Must be able to have no intervertebral fissure
- Must be able to have no infection
- Must be able to have no malignancy
- Must be able to have no neurological dysfunction
- Must be able to have no previous use of anti-osteoporosis drugs
- Must be able to have no inability to perform magnetic resonance imaging
- Must be able to have no prior back open surgery
- Must be able to have no other established contraindications for elective surgery
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Denosumab
1 ml (60 mg) of denosumab (Prolia; Amgen, Inc) subcutaneous injection plus intravenous placebo every 6 months
|
1 ml (60 mg) of denosumab (Prolia; Amgen, Inc) subcutaneous injection
Other Names:
oral placebo weekly
|
Active Comparator: alendronate
oral 70 mg alendronate sodium weekly.
|
oral placebo weekly
oral 70 mg alendronate sodium weekly plus subcutaneous placebo per 6 month.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Femoral neck BMD
Time Frame: up to 12 months
|
Femoral neck BMD were determined at baseline, 6 and 12 month via dual-energy X-ray
|
up to 12 months
|
C-terminal cross-linked type 1 collagen terminal peptide (CTX)
Time Frame: up to 12 months
|
Bone resorption marker, CTX were determined at baseline, 6 and 12 months after surgery
|
up to 12 months
|
Total hip BMD
Time Frame: up to 12 months
|
Total hip BMD were determined at baseline, 6 and 12 months via dual-energy X-ray.
|
up to 12 months
|
Procollagen type 1 n-terminal propeptide (P1NP)
Time Frame: up to 12 months
|
Bone formation marker, P1NP were determined at baseline, 6 and 12 months after surgery.
|
up to 12 months
|
Lumbar bone mineral density(BMD)
Time Frame: up to 12 months
|
Lumbar vertebral (L1 to L4, except the surgery segment) BMD were determined at baseline, 6 and 12 months via dual energy X-ray
|
up to 12 months
|
Visual analog scale (VAS) back
Time Frame: up to 12 months
|
The VAS score for back pain were determined at baseline, 6 and 12 month.
Use a ruler about 10cm long, one side is marked with "0" and the other "10" respectively.
A score of 0 indicates no pain, 10 indicates the most unbearable pain
|
up to 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The EQ-5D Questionnaire
Time Frame: up to 12 month
|
The EuroQol five-dimension (EQ-5D) questionnaire evaluates health status consisting five dimensions: mobility, selfcare, performance of usual activities, pain or discomfort, and anxiety or depression.
After conversion, the index was between 0 and 1.0 (minimum score: 0, indicating worst health state; full score:1.0,
indicating full health).
|
up to 12 month
|
Adverse events
Time Frame: up to 12 month
|
The main adverse events including deep venous thrombosis, pneumonia, acute renal failure, pulmonary embolism, myocardial infarction, influenza, transfer to intensive care unit, joint pain, headache, nausea, osteonecrosis of the jaw, atypical femoral fracture and rash.
|
up to 12 month
|
Secondary fracture rate
Time Frame: up to 12 month
|
Secondary fracture rate containing vertebral fracture and non-vertebral fracture was assessed at 12 month after surgery.
The lowest score was 0, the highest score was 100%.
The lower score 0 represents no secondary fracture.
|
up to 12 month
|
The Roland-Morris Disability Questionnaire
Time Frame: up to 12 month
|
The Roland-Morris Disability Questionnaire is scored by 24 adding up the number of items checked "yes" on different low back pain-related daily activity disabilities.
Total scores range from 0 to 24, with higher scores 24 indicating a higher level of disability related to low back pain and lowest 0 represents no back pain
|
up to 12 month
|
The QUALEFFO-31 Questionnaire
Time Frame: up to 12 month
|
The Quality of Life Questionnaire of the European Foundation for Osteoporosis-31 (QUALEFFO-31), which contains three domains including pain, physical function, and mental function.
This scale is assessed on a scale of 0 to 100, with 0 indicating the highest QoL and 100 the lowest
|
up to 12 month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 3, 2021
Primary Completion (Anticipated)
September 20, 2023
Study Completion (Anticipated)
October 25, 2023
Study Registration Dates
First Submitted
December 15, 2022
First Submitted That Met QC Criteria
December 21, 2022
First Posted (Actual)
December 22, 2022
Study Record Updates
Last Update Posted (Estimate)
February 21, 2023
Last Update Submitted That Met QC Criteria
February 18, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ShenzhenPH06
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Denosumab Allergy
-
Shenzhen People's HospitalCompleted
-
Shenzhen People's HospitalWithdrawn
-
Shenzhen People's HospitalCompletedOsteopenia | Spine Fusion | Denosumab AllergyChina
-
Shenzhen People's HospitalRecruiting
-
University of RochesterNational Institute of Allergy and Infectious Diseases (NIAID)Not yet recruitingEgg Allergy | Food Allergy Peanut | Food Allergy in Infants | Allergy and Immunology | Peanut and Nut AllergyUnited States
-
Hong Kong Sanatorium & HospitalChinese University of Hong KongTerminatedAllergy to Fish | Allergy to Shrimp | Allergy to CrabHong Kong
-
Abionic SAJohns Hopkins University; NAMSAWithdrawnAllergy | Allergic Asthma | Allergy to Cats | Allergy to House Dust | Allergy Cockroach | Allergy to Dog Dander (Finding) | Allergy MoldUnited States
-
King's College LondonGuy's and St Thomas' NHS Foundation TrustUnknownEgg Allergy | Food Allergy | Food Allergy in Children | Milk Allergy | Food Allergy in Infants | Nut Allergy | Food Allergen SensitisationUnited Kingdom
-
Peking University Third HospitalCancer Institute and Hospital, Chinese Academy of Medical Sciences; Beijing... and other collaboratorsRecruitingCow Milk Allergy | Food Allergy in ChildrenChina
-
King's College LondonKing's College Hospital NHS Trust; University College London Hospitals; Cambridge... and other collaboratorsRecruitingEgg Allergy | Food Allergy | Food Allergy in Children | Milk Allergy | Food Allergy in Infants | Nut Allergy | Food Allergen SensitisationUnited Kingdom
Clinical Trials on Denosumab
-
AmgenCompletedOsteoporosis | Osteopenia | Low Bone Mineral Density | Low Bone Mass | Males With Osteoporosis
-
GlaxoSmithKlineCompletedOsteoporosis, PostmenopausalKorea, Republic of
-
AmgenCompletedPostmenopausal OsteoporosisUnited States, Denmark, Poland, Canada
-
AmgenCompletedHealthy VolunteerUnited States
-
Samsung Bioepis Co., Ltd.CompletedPostmenopausal OsteoporosisPoland
-
Luye Pharma Group Ltd.ParexelCompleted
-
Borstkanker Onderzoek GroepAmgenWithdrawn
-
Swiss Group for Clinical Cancer ResearchActive, not recruitingMetastatic Breast Cancer | Bone Metastases | Metastatic Prostate CancerSwitzerland, Germany, Austria
-
National Cancer Institute (NCI)TerminatedOvarian CarcinomaUnited States, Israel